Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Aiolos Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"GSK Enters Agreement to Acquire Aiolos Bio","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"GSK Completes Acquisition of Aiolos Bio for Up to $1.4 Bln","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Aiolos Bio

    Menu

    Aiolos Bio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Aiolos Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GSK Completes Acquisition of Aiolos Bio for Up to $1.4 Bln

              Details:

              The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin monoclonal antibody, which is being evaluated in the treatment of asthma, chronic rhinosinusitis with nasal polyps, nasal polyps.

              Lead Product(s): AIO-001

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AIO-001

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: GSK

              Deal Size: $1,400.0 million Upfront Cash: $1,000.0 million

              Deal Type: Acquisition February 15, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Aiolos Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GSK Enters Agreement to Acquire Aiolos Bio

              Details:

              The acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting anti-thymic stromal lymphopoietin monoclonal antibody for adult patients with asthma, with potential for additional indications including chronic rhinosinusitis with nasal polyps.

              Lead Product(s): AIO-001

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AIO-001

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: GSK

              Deal Size: $1,400.0 million Upfront Cash: $1,000.0 million

              Deal Type: Acquisition January 09, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Aiolos Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody

              Details:

              The net proceeds will be used to advance company's lead drug candidate, AIO-001, an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, into a Phase 2 clinical trial in moderate-to-severe asthma patients.

              Lead Product(s): AIO-001

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AIO-001

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Atlas Venture

              Deal Size: $245.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing October 24, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY